ArticlePharmacoEconomics - open2023

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.

Andre Verhoek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.